EyeGene Inc
EyeGene Inc. engages in the research and development of biopharmaceutical drugs for the treatment and prevention of age-related diseases in South Korea. Its product pipeline comprises EG-Mirotin, which has completed Phase 2a clinical trial to treat diabetic retinopathy; EG-Decorin which completed Phase 2 clinical trial for the treatment of pressure ulcers and wound healing; and EG-Myocin, which h… Read more
EyeGene Inc (185490) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.021x
Based on the latest financial reports, EyeGene Inc (185490) has a cash flow conversion efficiency ratio of -0.021x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩-904.39 Million) by net assets (₩44.06 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
EyeGene Inc - Cash Flow Conversion Efficiency Trend (2014–2024)
This chart illustrates how EyeGene Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
EyeGene Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of EyeGene Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Garden Stage Limited Ordinary Shares
NASDAQ:GSIW
|
-0.172x |
|
Latvian Forest Company AB (publ)
F:2FD
|
0.003x |
|
Hun Yenilenebilir Enerji Uretim AS
IS:HUNER
|
0.014x |
|
Borlease Otomotiv A.S.
IS:BORLS
|
0.381x |
|
Pusan Cast Iron Co., Ltd.
KO:005030
|
0.020x |
|
TINYBUILD REGSCAT3 DL-001
F:8Z3
|
N/A |
|
WIN HANVERKY
MU:N2R
|
0.035x |
|
CyberCatch Holdings Inc.
V:CYBE
|
2.671x |
Annual Cash Flow Conversion Efficiency for EyeGene Inc (2014–2024)
The table below shows the annual cash flow conversion efficiency of EyeGene Inc from 2014 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ₩50.32 Billion | ₩-12.17 Billion | -0.242x | +22.45% |
| 2023-12-31 | ₩64.33 Billion | ₩-20.07 Billion | -0.312x | -12.09% |
| 2022-12-31 | ₩66.73 Billion | ₩-18.57 Billion | -0.278x | +17.49% |
| 2021-12-31 | ₩88.97 Billion | ₩-30.00 Billion | -0.337x | +55.40% |
| 2020-12-31 | ₩12.90 Billion | ₩-9.75 Billion | -0.756x | -72.94% |
| 2019-12-31 | ₩19.03 Billion | ₩-8.32 Billion | -0.437x | -36.42% |
| 2018-12-31 | ₩23.34 Billion | ₩-7.48 Billion | -0.321x | -12.64% |
| 2017-12-31 | ₩23.75 Billion | ₩-6.76 Billion | -0.285x | +23.06% |
| 2016-12-31 | ₩16.19 Billion | ₩-5.99 Billion | -0.370x | -87.96% |
| 2015-12-31 | ₩22.76 Billion | ₩-4.48 Billion | -0.197x | +68.29% |
| 2014-12-31 | ₩3.85 Billion | ₩-2.39 Billion | -0.621x | -- |